Bristol UFT Review Standards Questioned By Rep. Bliley In Letter To FDA
Bristol-Myers Squibb's oral colorectal cancer therapy UFT should be available as a "gentler" alternative to regimens containing Pharmacia's Camptosar, House Commerce Committee Chairman Bliley (R-Va.) told FDA in an April 17 letter to Commissioner Henney.
You may also be interested in...
Bristol plans to reallocate some of the money reserved for the launch of the antihypertensive Vanlev to help revive the cholesterol-lowering agent Pravachol.
Bristol-Myers Squibb's submission of two separate NDAs for the combination use of UFT and leucovorin appears to be a new filing and approval strategy for the development of bundled multi-ingredient products.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011